Screener
Palvella Therapeutics PVLA Income Tax
Income Tax at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: Palvella Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210463
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Interest income, net | 1,073 | 752 |
| Other income (expense), net | (32) | 224 |
| Loss before income taxes | (15,767) | (8,185) |
| Income tax benefit (expense) | — | — |
| Net loss | $(15,767) | $(8,185) |
| Other comprehensive loss: | ||
| Unrealized gain on investments | 4 | — |
| Foreign currency translation gain (loss) | 8 | (6) |
Item 1. Financial Statements.
FAQ
- What is Palvella Therapeutics's income tax?
- Palvella Therapeutics (PVLA) reported income tax of $0 in Q1 2026.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.
Ask your AI about Palvella Therapeutics's income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude